332083-22-4

Upstream product

• 1125-88-8 benzaldehyde dimethyl acetal 
• 3370-81-8 3-O-methyl-D-glucopyranose 

Downstream Products

• 332083-33-7 6-[4-acetoxy-6-(5-acetoxy-6-allyloxy-2-benzyloxymethyl-4-methoxy-tetrahydro-pyran-3-yloxy)-2-acetoxymethyl-5-benzyloxy-tetrahydro-pyran-3-yloxy]-4,5-dimethoxy-3-(4-oxo-pentanoyloxy)-tetrahydro-pyran-2-carboxylic acid benzyl ester 
• 332083-23-5 Allyl 2-O-acetyl-6-O-benzyl-3-O-methyl-α-D-glucopyranoside 

Relevant academic research and scientific papers

Experimental proof for the structure of a thrombin-inhibiting heparin molecule

Kinetic studies of thrombin inhibition by antithrombin in the presence of heparin have shown that thrombin binds to heparin in a preformed heparin-antithrombin complex. To study the relative position of the thrombin binding domain and the antithrombin bin

New synthetic heparin mimetics able to inhibit thrombin and factor Xa

Synthetic pentadeca-, heptadeca- and nonadecasaccharides, comprising an antithrombin III (AT HI) binding pentasaccharide prolonged at the non- reducing end by a thrombin binding domain have been obtained. The pentadecasaccharide is the shortest oligosaccharide able to catalyse thrombin inhibition by AT III. The nonadecasaccharide is a more potent thrombin inhibitor than standard heparin.